Industry sessions to watch at ASH 2026

An FDA decision is due on 13 May 2027, after Phase 3 data showed mezigdomide more than halved the risk of progression or death against standard care. It is BMS's second CELMoD pill: Zenbexus, from the same class, won accelerated approval on 13 August. The two carry $2.8bn in combined peak sales.

• Fri 11 Dec, 11:00

  The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care.

  BMS-only symposium chaired by Paul Richardson (Dana-Farber).

• Sat 12 Dec, 11:30

  Discover A New Oral-Based Regimen for First Relapse Myeloma.

  BMS product theater, matched to Zenbexus.

Three FDA applications are under review. Decisions are due on 30 November (GIST) and 30 December (non-advanced systemic mastocytosis), either side of ASH, with advanced systemic mastocytosis on 29 June 2027.

• Sat 12 Dec, 08:00

  Myth vs Mast Cell: Would You Recognize Systemic Mastocytosis?

  Industry forum where patients and clinicians discuss diagnosis, disease burden and unmet need.

• Fri 11 Dec, 19:00

  Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis.

  Co-funded with Blueprint Medicines (Sanofi), maker of the approved competitor Ayvakit.

The FDA approved Jaypirca for first-line CLL on 2 October, moving it up from later lines ten weeks before ASH. A further Phase 3 win came in May, with Jaypirca added to venetoclax and rituximab.

• Sun 13 Dec, 11:30

  See How Jaypirca (pirtobrutinib) is Sparking More Possibilities.

  Lilly product theater.

• Fri 11 Dec, 19:00

  Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL.

  Co-funded with Nurix and Genentech.

Lilly also co-funds three AstraZeneca-led Friday symposia, two in CLL and one in mantle cell lymphoma.

AbbVie filed etentamig, a BCMA bispecific with monthly dosing, with the FDA on 27 October, after positive Phase 3 results in September.

• Fri 11 Dec, 07:00

  Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs.

  AbbVie is one of five funders, with AstraZeneca, BMS, CellCentric and J&J.

The FDA approved Besremi for ET on 31 August, the first new ET treatment in nearly 30 years. PharmaEssentia has three sessions around it, more than any other single-product company in this list.

• Sun 13 Dec, 08:00

  Changing the ET Conversation: A New Paradigm in ET Management.

  Product theater.

• Fri 11 Dec, 11:00

  Show Me the Data: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera.

  PharmaEssentia-only symposium.

• Fri 11 Dec, 15:00

  Cases and Conversations: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms.

  Co-funded with Geron and GSK.

Epkinly with lenalidomide had a positive Phase 3 result in DLBCL in June and won European approval in follicular lymphoma in July. In the same month, a separate Phase 3 of Epkinly alone missed overall survival, its main US goal.

• Mon 14 Dec, 12:15

  Unlocking the Potential for a Bispecific Antibody in 2L+ FL and 3L+ DLBCL.

  Genmab and AbbVie product theater.

• Fri 11 Dec, 11:00

  Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum.

  Genmab-only symposium.

The FDA approved Mimrylo on 28 August as the first hepcidin mimetic, a new class that reduces the need for regular blood draws. This is its first ASH as a marketed drug, and it is one of only two brands named in a session title. Takeda's partner on Mimrylo is Protagonist Therapeutics.

• Sat 12 Dec, 08:00

  Navigating PV with MIMRYLO: A Patient-Centered Clinical Conversation.

  Takeda industry forum with a patient perspective.

Mimrylo's Phase 3 data is also on the agenda of PharmaEssentia's Friday symposium on PV and essential thrombocythemia.

Etavopivat met both main goals in a pivotal Phase 3 trial in April, cutting pain crises and improving hemoglobin, and Novo plans to file with the FDA. Novo gained the drug through its $1.1bn acquisition of Forma Therapeutics.

• Mon 14 Dec, 12:15

  Building the Evidence: Novo Nordisk's Investigational Clinical Development in Sickle Cell Disease and Thalassemia.

  Novo industry theater.

• Fri 11 Dec, 07:00

  A Hematologist's Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond.

  Co-funded with Agios, Beam and Genetix, covering the new drug class etavopivat belongs to.

This is Blenrep's first full ASH since its US return in October 2025. A permanent US billing code took effect on 1 July, which GSK tied to community oncology, where it says about 70% of myeloma patients are treated.

• Mon 14 Dec, 12:15

  Expanding Community Therapy Options in Relapsed or Refractory Multiple Myeloma: A BCMA-Targeted Option.

  GSK product theater.

• Fri 11 Dec, 19:00

  Addressing Community Oncologists' Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma.

  Co-funded with Genentech.

BCMA is the busiest target at this ASH: Pfizer and Regeneron also run BCMA product theaters, and AbbVie's etentamig is under FDA review.

Positive Phase 3 results in ITP were presented at ASH last year. Novartis plans to file in ITP in 2027, together with first-line data. Ianalumab also holds FDA Breakthrough Therapy designation in Sjögren's disease, granted in January.

• Fri 11 Dec, 07:00

  B-Cell-Directed Therapies in Immune Thrombocytopenia: Real-World Practice.

  Novartis-only symposium, chaired by David Kuter (Massachusetts General Hospital), on fitting new B-cell drugs into ITP care.

ITP is contested at this meeting: Sanofi runs a Wayrilz product theater on Sat 12 Dec.